Heart failure: What does ejection fraction have to do with it?

Journal of Cardiology

Volumn 62, Issue 1, 2013, Pages 1-3

  Iwano, Hiroyuki ^a   Little, William C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Ejection fraction; Heart failure; Heart failure with preserved ejection fraction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; SILDENAFIL; SPIRONOLACTONE;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOGENIC SHOCK; DIASTOLIC DYSFUNCTION; DYSPNEA; EXERCISE TOLERANCE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART STROKE VOLUME; HOSPITALIZATION; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINUS RHYTHM; SYSTOLIC DYSFUNCTION; VASODILATATION;

EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION;

HEART FAILURE; HUMANS; STROKE VOLUME;

EID: 84880044020     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.02.017     Document Type: Review

References (31)

1. Little W.C., Zile M.R. HFpEF: cardiovascular abnormalities not just co-morbidities. Circ Heart Fail 2012, 5:669-671.
2. Jessup M., Abraham W.T., Casey D.E., Feldman A.M., Francis G.S., Ganiats T.G., Konstam M.A., Mancini D.M., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
3. Konstam M.A., Kramer D.G., Patel A.R., Maron M.S., Udelson J.E. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011, 4:98-108.
4. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
5. Little W.C. Assessment of normal and abnormal cardiac function. Heart disease: a textbook of cardiovascular medicine 2001, 479-502. WB Saunders Company, Philadelphia. E. Braunwald, D.P. Zipes, P. Libby (Eds.).
6. Brucks S., Little W.C., Chao T., Kitzman D.W., Wesley-Farrington D., Gandhi S., Shihabi Z.K. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 2005, 95:603-606.
7. Kitzman D.W., Little W.C., Brubaker P.H., Anderson R.T., Hundley W.G., Marburger C.T., Brosnihan B., Morgan T.M., Stewart K.P. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150.
8. Lam C.S.P., Roger V.L., Rodeheffer R.J., Bursi F., Borlaug B.A., Ommen S.R. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction: from Olmstead County, Minnesota. Circulation 2007, 115:1982-1990.
9. Zile M.R., Gottdiener J.S., Hetzel S.J., McMurray J.J., Komajda M., McKelvie R., Baicu C.F., Massie B.M., Carson P.E. I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011, 124:2491-2501.
10. Gaasch W.H., Zile M.R. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011, 58:1733-1740.
11. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011, 32:670-679.
12. Borlaug B.A., Kass D.A. Ventricular-vascular interaction in heart failure. Cardiol Clin 2011, 29:447-459.
13. Little W.C., Cheng C.P. Left ventricular-arterial coupling in conscious dogs. Am J Physiol 1991, 261:H70-H76.
14. Little W.C., Pu M. Left ventricular-arterial coupling. J Am Soc Echocardiogr 2009, 22:1246-1248.
15. Schwartzenberg S., Redfield M.M., From A.M., Sorajja P., Nishimura R.A., Borlaug B.A. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012, 59:442-451.
16. Ahmed A., Rich M.W., Fleg J.L., Zile M.R., Young J.B., Kitzman D.W., Love T.E., Aronow W.S., Adams K.F., Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114:397-403.
17. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003, 362:777-781.
18. Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
19. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Anderson S., Donovan M., Iverson E., Staiger C., Ptaszynska A. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
20. Hernandez A.F., Hammill B.G., O'Connor C.M., Schulman K.A., Curtis L.H., Fonarow G.C. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009, 53:184-192.
21. Desai A.S., Lewis E.F., Li R., Solomon S.D., Assmann S.F., Boineau R., Clausell N., Diaz R., Fleg J.L., Gordeev I., McKinlay S., O'Meara E., Shaburishvili T., Pitt B., Pfeffer M.A. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011, 162:966-972.
22. Guazzi M., Vicenzi M., Arena R., Guazzi M.D. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011, 4:8-17.
23. Redfield M.M., Borlaug B.A., Lewis G.D., Mohammed S.F., Semigran M.J., Lewinter M.M., Deswal A., Hernandez A.F., Lee K.L., Braunwald E. Heart Failure Clinical Research Network. PhosphdiesteRasE-5 Inhibition to Improve Clinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail 2012, 5:653-659.
24. Solomon S.D., Zile M., Pieske B., Voors A., Shah A., Kraigher-Krainer E., Shi V., Bransford T., Takeuchi M., Gong J., Lefkowitz M., Packer M., McMurray J.J. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor Icz696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
25. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Jánosi A., Kamenský G., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
26. Gissi-HF Investigators, Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
27. Fukuta H., Sane D.C., Brucks S., Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005, 112:357-363.
28. Maurer M.S., Hummel S.L. Heart failure with a preserved ejection fraction: what is in a name?. J Am Coll Cardiol 2011, 58:275-277.
29. Ather S., Chan W., Bozkurt B., Aguilar D., Ramasubbu K., Zachariah A.A., Wehrens X.H., Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominately male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012, 59:998-1005.
30. Braunstein J.B., Anderson G.F., Gerstenblith G., Weller W., Niefeld M., Herbert R., Wu A.W. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003, 42:1226-1233.
31. Mohammed S.F., Borlaug B.A., Roger V.L., Mirzoyev S.A., Rodeheffer R.J., Chirinos J.A., Redfield M.M. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 2012, 5:710-719.